世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のアンチセンスとRNAi治療市場 2019-2023年

Global Antisense and RNAi Therapeutics Market 2019-2023

IRTNTR30107

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
113

サマリー

この調査レポートは世界のアンチセンスとRNAi治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Antisense and RNAi Therapeutics
Antisense and RNAi therapeutics are novel therapeutic options with potential to treat diseases such as chronic liver and cardiovascular diseases, Huntington disease, and even rare diseases.
Technavio’s analysts forecast the Global Antisense and RNAi Therapeutics Market to grow at a CAGR of 8.67% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the antisense and RNAi therapeutics market. To calculate the market size, the report considers the revenue generated from the application of antisense and RNAi therapeutics across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, antisense and RNAi therapeutics market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Alnylam Pharmaceuticals
- Bausch Health
- Biogen
- Sarepta Therapeutics
Market driver
- High target affinity and specificity of RNAi therapeutics
- For a full, detailed list, view our report

Market challenge
- High price of RNAi drugs
- For a full, detailed list, view our report

Market trend
- Growing potential to address multiple therapy areas
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Antisense therapy - Market size and forecast 2018-2023
- RNAi therapy - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Cardiovascular diseases
- Cancer
- Metabolic disorders
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Alnylam Pharmaceuticals
- Bausch Health
- Biogen
- Sarepta Therapeutics
PART 16: APPENDIX
- Research methodology
- List of abbreviations
PART 17: EXPLORE TECHNAVIO

?
Exhibit 01: Global biologic therapeutics market
Exhibit 02: Segments of global biologic therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: List of pipeline molecules for antisense and RNAi therapeutics
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antisense therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antisense therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: RNAi therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: RNAi therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Pipeline molecules for cancer treatment
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Alnylam Pharmaceuticals - Vendor overview
Exhibit 47: Alnylam Pharmaceuticals - Business segments
Exhibit 48: Alnylam Pharmaceuticals - Organizational developments
Exhibit 49: Alnylam Pharmaceuticals - Geographic focus
Exhibit 50: Alnylam Pharmaceuticals - Key offerings
Exhibit 51: Bausch Health - Vendor overview
Exhibit 52: Bausch Health - Business segments
Exhibit 53: Bausch Health - Organizational developments
Exhibit 54: Bausch Health - Geographic focu
Exhibit 55: Bausch Health - Segment focus
Exhibit 56: Bausch Health - Key offerings
Exhibit 57: Biogen - Vendor overview
Exhibit 58: Biogen - Business segments
Exhibit 59: Biogen - Organizational developments
Exhibit 60: Biogen - Geographic focus
Exhibit 61: Biogen - Key offerings
Exhibit 62: Sarepta Therapeutics - Vendor overview
Exhibit 63: Sarepta Therapeutics - Business segments
Exhibit 64: Sarepta Therapeutics - Organizational developments
Exhibit 65: Sarepta Therapeutics - Geographic focus
Exhibit 66: Sarepta Therapeutics - Key offerings
Exhibit 67: Validation techniques employed for market sizing
Exhibit 68: List of abbreviations


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る